A2B adenosine receptor antagonists
US6825349B2 · kind B2 · utility
42Cited by
12References
31Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2002 |
| Grant date | Nov 30, 2004 |
| Priority date | — |
| Expiry date | Nov 21, 2022 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D473/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are novel A2B adenosine receptor antagonists compounds having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.